Edition:
United Kingdom

Biofrontera AG (B8FGn.DE)

B8FGn.DE on Xetra

5.94EUR
11:10am BST
Change (% chg)

€-0.03 (-0.50%)
Prev Close
€5.97
Open
€5.98
Day's High
€5.99
Day's Low
€5.93
Volume
13,169
Avg. Vol
172,857
52-wk High
€7.63
52-wk Low
€2.91

Select another date:

Mon, Mar 5 2018

BRIEF-Biofrontera: European Commission Approves Use Of Ameluz In Combination With Daylight Photodynamic Therapy

* PTA-ADHOC: BIOFRONTERA AG: EUROPEAN COMMISSION APPROVES USE OF AMELUZ IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biofrontera Closes $12.9 Million Firm Commitment IPO Of American Depositary Shares

* BIOFRONTERA AG ANNOUNCES CLOSING OF $US12.9 MILLION FIRM COMMITMENT INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biofrontera announces pricing of $12 mln firm commitment public offering of ADS & Nasdaq listing

* BIOFRONTERA AG ANNOUNCES PRICING OF US$12 MILLION FIRM COMMITMENT PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES AND NASDAQ LISTING

BRIEF-Biofrontera to Issue Up To 6 Mln New Shares Of EUR 1 Each

* ‍SUBSCRIPTION PRICE FOR NEW SHARES WAS SET AT EUR 4.00 PER NEW SHARE ON FEBRUARY 9, 2018​

BRIEF-Biofrontera Sets Price For New Shares At 4.00 Euros

* ‍SUBSCRIPTION PRICE FOR NEW SHARES WAS SET TODAY AT EUR 4.00​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biofrontera AG Says Estimate That IPO Price Will Be Between $11 And $13 Per ADS

* BIOFRONTERA AG SAYS ESTIMATE THAT THE INITIAL PUBLIC OFFERING PRICE WILL BE BETWEEN $11.00 AND $13.00 PER ADS – SEC FILING‍​

BRIEF-Biofrontera Adjusts Expectations With Regard To Subscription Price Of New Shares

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA AG ADJUSTS EXPECTATIONS WITH REGARD TO SUBSCRIPTION PRICE OF NEW SHARES

BRIEF-Biofrontera Resolves On Capital Increase

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA AG RESOLVES ON CAPITAL INCREASE

BRIEF-Biofrontera Receives Favorable CHMP Assessment For Ameluz In Combination With Daylight Photodynamic Therapy

* PTA-ADHOC: BIOFRONTERA AG: BIOFRONTERA RECEIVES FAVORABLE CHMP ASSESSMENT FOR AMELUZ® IN COMBINATION WITH DAYLIGHT PHOTODYNAMIC THERAPY

BRIEF-Biofrontera AG Says Estimate That IPO Price Will Be Between $8.80 And $10.80 Per ADS

* BIOFRONTERA AG SAYS ESTIMATE THAT INITIAL PUBLIC OFFERING PRICE WILL BE BETWEEN $8.80 AND $10.80 PER ADS - SEC FILING Source text : (http://bit.ly/2DCrvYW) Further company coverage:

Select another date: